All In Biotech

Drug Trial Radar · NCT05704543

Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

A Single-Dose Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of SUBLOCADE at Alternative Injection Locations in Adults

Last checked: Nov 20, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

132

Actual

Start

Mar 1, 2023

Primary completion

Nov 1, 2023

Study completion Nov 1, 2023

Sponsor

Lead sponsor
Indivior Inc.Industry
Sponsor type
Industry
First posted
Jan 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Extended-release buprenorphine (SUBLOCADE®) injection is currently approved for subcutaneous administration in the abdomen for treatment of opioid use disorder (OUD). Having alternative injection sites is desirable to provide additional flexibility to patients, particularly for those who may prefer less visible or more convenient injection locations. The primary objective of this study is to assess the relative bioavailability of extended-release buprenorphine when administered at alternative injection locations (test treatments), in comparison to the abdomen (reference treatment).

Conditions

  • Opioid Use Disorder

Interventions

  • Buprenorphine Extended-Release InjectionDrug

    Administered as a subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration-time Curve From Study Day 1 to Day 29 (AUC0-28days) of BuprenorphineTime frame: Day 1 at predose and at 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48 hours post-dose and on Days 4, 6, 8, 11, 15, 18, 22, 25, and 29
  2. Maximum Observed Plasma Concentration (Cmax) of BuprenorphineTime frame: Day 1 at predose and at 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48 hours post-dose and on Days 4, 6, 8, 11, 15, 18, 22, 25, and 29

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Artemis Institute for Clinical Research

    San Diego, California

  • Research Centers of America

    Hollywood, Florida

  • Miami Lakes Medical Research

    Miami Lakes, Florida

  • Rivus Wellness and Research Institute

    Oklahoma City, Oklahoma

  • InSite Clinical Research, LLC

    DeSoto, Texas

  • Pillar Clinical Research, LLC

    Richardson, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.